Trigger Finger After Menopause: What the Estrogen Research Shows

What is trigger finger, and what is actually happening in the tendon?

Each finger that bends has a tendon running along its underside. That tendon passes through a series of tight fibrous tunnels called pulleys, which keep it snug against the bone as it glides. The first and tightest of these, the A1 pulley, sits right at the base of the finger.

In trigger finger, that pulley thickens, or the tendon running through it swells. The two no longer glide smoothly together. The finger catches partway through bending, then releases with a sudden snap, and in more advanced cases it locks bent and has to be straightened by hand. Most cases happen with no clear trauma or injury behind them at all.

Here is what a large 2026 study found about who this actually affects.

What a 2026 population study found

• Among 465,763 patients with trigger finger, the thumb (35.2%), middle finger (34.1%), and ring finger (26.0%) were most commonly affected
• Patients with trigger finger were 63.0% female, against 54.3% female in the general comparison population
• Average age at diagnosis was 60.6 years, against 39.5 in the comparison population
• 16.6% of patients underwent surgical release within three years of diagnosis

Why are women in their 50s and 60s so disproportionately affected?

The age and sex pattern above is not new. Clinicians have described a peak incidence of trigger finger specifically in women aged 50 to 59 for decades, and researchers writing about that pattern have noted the predisposition in that age group is often linked to rheumatic conditions, but probably not solely so, pointing toward some other degenerative, postmenopausal factor at work as well.

That is a real gap in the research. A large population study can show that trigger finger clusters in postmenopausal women far more than chance would predict. It cannot, on its own, show why. The next two sections cover what the mechanism research has tried to fill that gap with.

What happens when estrogen is removed completely, rather than gradually?

Natural menopause removes estrogen gradually, over years, which makes it hard to isolate as a single cause in a population study. Aromatase inhibitors, a class of drug used in breast cancer treatment, do something closer to a clean experiment. They block the enzyme that makes the body's remaining estrogen, dropping estrogen levels further and faster than natural menopause does on its own.

A 2015 case report in the Yonsei Medical Journal described a 49-year-old woman on the aromatase inhibitor anastrozole who developed painful trigger thumbs in both hands. During surgery, doctors found the A1 pulley thickened in both thumbs, with the flexor tendon catching as it passed through. The authors proposed that aromatase inhibitors "reduce the antinociceptive effects of estrogen by complete estrogen depletion," lowering the pain threshold.

That single case is not proof on its own. A larger, more recent data source matters here too.

A 2026 pharmacovigilance study in Frontiers in Oncology analyzed real-world adverse-event reports for three aromatase inhibitors, anastrozole, letrozole, and exemestane, filed with the FDA from 2004 through early 2024. Trigger finger and tenosynovitis stenosans showed up as a significant disproportionality signal for this drug class. That means these conditions were reported at a notably higher rate for aromatase-inhibitor users than the overall reporting pattern would predict. It is a reporting-rate signal from a side-effect database, not a measured incidence rate, and it should be read as exactly that.

Two findings, read together with their real limits stated.

Reading this evidence honestly

• Both findings come from women on a drug that removes estrogen, not from natural menopause directly
• The case report is one patient. It illustrates a mechanism; it does not establish a rate
• The pharmacovigilance signal measures how disproportionately a side effect was reported, not how often it actually occurs
• Together, they are the clearest human signal available that losing estrogen, specifically, rather than just aging, tracks with this exact tendon problem

What does the lab research say about estrogen receptors in tendon tissue?

The tissue-level mechanism behind that human signal comes from animal research. A 2018 study published in PLOS ONE, led by Hsieh and colleagues, used ovariectomized rats, animals with their ovaries surgically removed to eliminate estrogen. The researchers paired that with tendon cell cultures under repeated mechanical stretching.

The findings were specific. Estrogen receptor-beta expression and tendon cell death both rose in the estrogen-deficient tissue, and both tracked with how severe the tendon damage became.

That is animal tissue, not a living woman's hand, and it should be stated as exactly that. What it offers is a plausible biological reason the human pattern above exists. Tendon tissue carries estrogen receptors, those receptors appear to respond to mechanical use, and removing estrogen appears to change how that tissue responds to the stress of daily gripping and bending.

What does shilajit's own tendon research show?

No trial has ever tested shilajit, or any Optimum product, against trigger finger specifically. That gap should be stated before anything else in this section, not after.

What exists instead is separate human research on shilajit's fulvic acid compound and connective tissue more broadly. An 8-week human trial, published by Das and colleagues in 2016, gave 16 adults oral shilajit and took muscle tissue biopsies. The group was 10 women and 6 men with a mean age of 35.7.

The biopsies showed a cluster of 17 collagen-related genes switched on, including more than an 80-fold rise in one type 1 collagen gene by the RT-PCR measurement. Separately, fulvic acid reduced COX-2 and PGE2, two inflammation signals, in human monocyte cells in lab research. It did so by blocking the same molecular pathway that ibuprofen and Celebrex target.

Four limits are worth stating plainly before this evidence travels any further.

The honest limits of this evidence

• The Das 2016 trial measured muscle tissue, not tendon, and its subjects were not postmenopausal, averaging 35.7 years old
• The fulvic acid anti-inflammatory research was conducted in isolated human cells in a lab, not inside a living tendon
• Neither study measured trigger finger, hand function, or any tendon outcome at all
• No study has tested shilajit in a postmenopausal woman's tendon tissue specifically, and none has tested it against trigger finger in anyone

How does that compare to what actually treats trigger finger?

The table exists to be honest about where the real evidence sits, not to oversell shilajit's place in it. Trigger finger has well-studied, effective treatments. The estrogen mechanism research above explains part of why it clusters in postmenopausal women; it does not substitute for those treatments.

See Optimum Shilajit

Optimum Shilajit is sourced from the Altai mountains and standardized for fulvic acid content, the compound behind its own documented connective-tissue research. See Optimum Shilajit.

See Optimum Shilajit